GLOW combines three peptides in one pen. The useful thing to understand about any blend is that its evidence base is not a single thing — it is three separate literatures of differing depth, plus a gap where evidence about the combination would be.
GLOW is supplied as a single 3mL pen containing 70mg in total: GHK-Cu at 50mg, BPC-157 at 10mg and TB-500 at 10mg.
The great majority of the mass is GHK-Cu. That is worth noting when reading about the blend, because discussion often treats the three as equal contributors when the formulation does not.
Each component has its own research literature, summarised briefly here and covered in depth in the dedicated articles linked below.
The practical rationale for supplying peptides pre-combined is straightforward: a laboratory running all three together would otherwise perform three separate reconstitutions and three transfers, each of which introduces handling variability and a contamination opportunity.
A single pen removes those steps. That is a workflow argument, not a scientific claim, and it is the honest reason blends exist.
There is no controlled study of the GLOW combination. This is the single most important thing to understand about it.
It is tempting to reason that if component A is studied for one thing and component B for another, the combination does both. That inference is not safe. Combinations can behave differently from their parts — effects may not be additive, and interactions are not predictable from component data alone.
The accurate position is: three components with individual literatures of varying strength, and no evidence about the combination. We state that rather than implying otherwise.
The three blends in the range overlap deliberately, which makes comparison straightforward.
This article is reference material describing published research. It is not medical advice, not a therapeutic claim, and contains no dosing or administration guidance.